HAErmony1: A Phase 1/2, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Efficacy of BMN 331, an Adeno-Associated Virus (AAV) Vector-Mediated Gene Transfer of Human SERPING
Clinical Trial Grant
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
BioMarin Pharmaceutical, Inc.
Start Date
August 2, 2022
End Date
September 30, 2027
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
BioMarin Pharmaceutical, Inc.
Start Date
August 2, 2022
End Date
September 30, 2027